Vedolizumab‐associated pulmonary manifestations in children with ulcerative colitis

摘要

Abstract What is known and Objective The off‐label use of vedolizumab (VDZ) for inflammatory bowel disease in children is increasing. We report on possibly the first case of VDZ‐associated pulmonary manifestations in paediatrics. Case summary This report details the case of a 13‐year‐old child with ulcerative colitis who was initiated on VDZ due to persistent active disease. After the first three doses, he developed a persistent and productive cough. Microbiological work‐up was normal. VDZ discontinuation led to the resolution of symptoms. What is new and conclusion To our knowledge, this is the first case report of VDZ‐associated pulmonary manifestations in paediatrics. A direct, pro‐inflammatory effect of VDZ has been hypothesized, but further studies are warranted.